生物标记物解决方案中心

覆盖我们广泛的全球实验室测试能力的科学思想领导和指导。在药物研发生命周期的各个阶段提供定制化的端到端生物标记物解决方案。

Industry insights to drive your biomarker strategy forward

  • PhD-level leaders that can extend your team and / or help you develop a comprehensive biomarker strategy

  • Industry-relevant insights and specialized therapeutic area biomarker expertise

  • Customized consultation for biomarker strategy solutions

photo of a team talking during a meeting
您的需求

To leverage the benefits of a biomarker strategy – including 3x greater probability of successful transition from Phase I to regulatory approval1 – early insights and thoughtful strategy design are critical. Continuity with a single partner, who understands and connects the science, can also enable more insightful clinical trial design and better clinical outcomes.

1BIO, Biomedtracker, Amplion 2016.pdf. www.bio.org
我们的能力

Whether you need support in building your biomarker program strategy or seek to extend your team with industry expertise, we can enable bringing your treatment to market more rapidly. 

PhD-level Leaders with Therapeutic Area Expertise

Our Biomarker Solution Center (BSC) experts work with you to develop biomarker strategies and solutions - from discovery through commercialization - to support your drug development needs. We can identify gaps and provide mitigation strategies to build a customized strategy that integrates therapeutic-area biomarkers and best practices across your development plan.

The BSC has specialized expertise for the following areas:

ONCOLOGY: Including biomarkers of response and resistance for immuno-oncology and targeted oncology therapies
IMMUNOLOGY: Including biomarkers of immunological and inflammatory diseases
CARDIOVASCULAR AND METABOLIC DISEASE: Including biomarkers of diabetes, NASH, cardiovascular and renal disease
NEUROLOGY: Including biomarkers of neurodegenerative diseases

Strategy Design Consultation

Designed to engage clients early in the drug development process, providing advice from need identification through project completion, the BSC team can help you address all of your biomarker questions to develop a customized approach for your biomarker program.

  • Which is the most appropriate biomarker for my intended target?
  • What is the best biomarker to interrogate the mechanism of action?
  • Where should the biomarker be measured?
  • Which regulatory environment and technology best support my intended use?

Should further consultation be needed at any stage of drug development, the BSC team can also be engaged on a fee-for-service or value-in-kind basis. 

Streamlined Navigation Support

The Biomarker Solution Center can help guide your program into one of the Covance/LabCorp extensive network of laboratories and regulatory environments. We can also work with you to transfer proprietary assays dependent on your needs - all while maintaining the scientific partnership of the BSC.

An Experienced Approach to Biomarker Development

利用我们在生物标记物方面广泛、多学科的知识和治疗领域专业知识,帮助定义并设计针对您的研发需要量身定制的综合性生物标记物战略。 Whether you are searching for a specific biomarker or would like to explore available options, our database of 4,500 available assays and markers across Covance and LabCorp makes it easy to find the right support for your program.

认识团队成员
Suso J. Platero,博士 生物标记物解决方案中心主管 科文斯精准医药全球主管

Suso J. Platero,博士
生物标记物解决方案中心主管
科文斯精准医药全球主管

Suso Platero博士领导生物标记物解决方案中心,为客户提供生物标记物咨询服务与策略,利用科文斯和LabCorp实验室的资源支持生物标记物传递的开发。20多年来,他积累了丰富的合同研究组织、诊断和制药行业以及学术界相关经验,并时常与联邦机构以及肿瘤学和免疫肿瘤学领域的主要意见领袖打交道。

Platero博士为生物标记物的发现及其在临床试验中的应用以及研发生物标记物以支持伴随诊断(CDx)做出了贡献,并且近期协助为2019年通过FDA审批的一款药物研发出伴随诊断疗法。他是《Molecular Pathology in Drug Discovery and Development》一书的编辑,撰写了多篇著作并持有四项美国专利。   

Akanksha Gupta的照片

Akanksha Gupta,博士
生物标记物解决方案中心免疫学主管

Akanksha Gupta博士领导生物标记物解决方案中心的免疫学治疗团队,该团队利用科文斯和LabCorp的实验室资源提供生物标记物解决方案及策略。通过实施战略领导,他为生物标记物策略提供科学指引,整合创新技术、新兴科学知识、临床可行性以及对横跨多个治疗领域的精准医药疗法的监管要求,包括免疫炎症、免疫肿瘤学、呼吸道、皮肤病学和其他自身免疫疾病。

Gupta博士在制药行业拥有15多年经验,擅长药物研发、转化研究以及支持早期到后期资产的研发战略。她是超过30篇经同行评审的研究刊物、摘要和专利申请的著作者或合著者。

Katherine T. Landschulz,博士 生物标记物解决方案中心心血管/代谢疾病主管

Katherine T. Landschulz,博士
生物标记物解决方案中心心血管/代谢疾病主管

Katherine Landschulz博士于2010年加入科文斯,此前她曾在三家大型制药公司效力13年,负责为项目从药物筛选到III期研究的各个阶段提供支持。在科文斯,她为生物技术和大型制药公司提供生物标记物选择与策略开发、方法开发实验室安置以及资格/验证、可行性研究设计相关支持,并就在药物研发中使用转化和探索性生物标记物数据提供咨询服务。  

Landschulz博士在药物筛选和研发、基因组学和蛋白质组学生物标记物检测方法开发、转化生物标记物、临床药物基因组学和针对糖尿病/CV的生物标记物策略领域拥有广泛经验。她持有两项美国专利,并是广泛治疗领域数十篇出版物的合著者。

Maria J. Prendes,博士,理学硕士 生物标记物解决方案中心肿瘤学主管

Maria J. Prendes,博士,理学硕士
生物标记物解决方案中心肿瘤学主管

Maria Prendes博士领导生物标记物解决方案中心的肿瘤学治疗团队,并与客户合作,为临床试验的生物标记物选择、表征和开发提供指导。他的职责还包括支持伴随诊断(CDx)开发工作。  

Prendes博士专长于免疫肿瘤学、癌症基因学、癌症生物学和分子肿瘤学,并拥有15多年药物研发经验,负责为研究提供指导以发现新的肿瘤学临床标记物,并设计、开发和表征特定生物标记物靶点的抗体,这些生物标记物靶点将用作治疗剂,并用于伴随诊断检测方法的开发。她持有多项美国专利,并且是多篇期刊论著的著作者和合著者。